Galena Biopharma Inc (GALE), Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Could This Breast Cancer Vaccine Be a Game Changer?

Page 1 of 2

Breast cancer claims more than 40,000 lives in the United States annually and is one of the leading causes of death for females globally. However, every year biotech companies are making incredible advances in breast cancer treatments that could eventually eradicate this debilitating disease.

A breast cancer vaccine

One of the most promising new treatments is Galena Biopharma Inc (NASDAQ:GALE)‘s NeuVax, a breast cancer vaccine that attempts to stop recurrences of node-positive HER2-negative breast cancer. NeuVax works by stimulating the patient’s immune system to seek out and destroy residual cancer cells expressing the HER2/neu protein in patients who have achieved remission. The HER2/neu protein is often associated with colon, breast, ovarian, pancreatic, and bladder cancers.

Galena Biopharma Inc

HER2-negative breast cancer accounts for approximately 75% of all breast cancer cases. There is a 15% to 20% chance of breast cancer recurring, even following a mastectomy, which means that NeuVax could be a game-changing blockbuster treatment if approved. In phase 2 trials, patients dosed with the treatment showed a 5.6% recurrence rate compared to a 25.9% recurrence rate in the control arm — a 78.4% reduction in total recurrences.

Two major supporters

NeuVax is currently in a phase 3 trial for the stand-alone usage as a breast cancer vaccine, and in a phase 2 trial for combined use with Roche Holding Ltd. (ADR) (OTCBB:RHHBY)‘s Herceptin. Herceptin is one of the primary approved treatments for HER2 breast cancer, which generated $6 billion in sales last year.

Herceptin is a monoclonal antibody that attaches itself to the surface of a cancer cell to prevent it from receiving new growth signals. It can also alert the immune system to destroy the cancer cells to which it is attached. Therefore, using NeuVax’s ability to stimulate the immune system to actively seek out the cancer with Herceptin’s ability to starve and mark cancer cells could prove to be an incredibly potent combination. For Roche Holding Ltd. (ADR) (OTCBB:RHHBY), creating a new combined treatment could also soften the blow of Herceptin’s upcoming patent expiration in 2014.

In addition to Roche, another major company that believes in Galena Biopharma Inc (NASDAQ:GALE) is Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). Last December, Galena signed an agreement with Teva to commercialize NeuVax in Israel. Teva will provide marketing support and help NeuVax obtain regulatory approval in the region. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) also produces a generic version of AstraZeneca‘s breast cancer drug Arimidex, which is used for post-surgery treatment.

Abstral provides a steady revenue stream

Galena Biopharma Inc (NASDAQ:GALE) also acquired the U.S. commercialization rights for Abstral, a cancer pain medication, from Orexo AB in March. Abstral was approved by the FDA in 2011 as the first and only fentanyl sublingual tablet to treat patients with breakthrough (“spiking”) cancer pain in opioid tolerant patients, and generated $54 million in sales in Europe last year.

Bringing Abstral to the U.S. market will give the company a steady stream of revenue — a strength that many other speculative biotechs sorely lack. Last quarter, Galena Biopharma Inc (NASDAQ:GALE) only had $26.7 million in cash and equivalents, with $9.7 million in debt and a negative cash flow of $21.8 million.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!